Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Quince Therapeutics, Inc. (QNCX) Stock · SELL · CRISIS | LOPJLB

Quince Therapeutics, Inc. (QNCX)

Healthcare · Biotechnology · NASDAQ · US

$29.36+9.88%Close

SELLCRISIS · day 5

QNCX▼ SELL

$29.36+9.88%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-15

Market cap: $8M
Beta: 1.33
P/E (TTM): -0.39

Short % float: 20.21%
Days to cover: 3.0
SI change: -11.8%

1W: -4.30%
1M: -3.17%

vs SPY 1W: -5.86%
vs SPY 1M: -4.93%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport…

Employees: 38
Headquarters: US
Founded: 2019
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 278.4K
Float: 89.4%

quincetx.com ↗

Key executives

Dirk Thye — Chief Executive Officer, Chief Medical Officer & Director

Charles S. Ryan — President

Brendan Hannah — Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer

SEC filings

EDGAR · CIK 16627740 · QNCX

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish545.5%

Neutral436.4%

Bearish218.2%

L $68.00Avg $70.00H $72.00

Target$70.00+138.42%

Last$29.36

Company news

globenewswire.com · 16h ago

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

defenseworld.net · 3d ago

Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans

seekingalpha.com · 3d ago

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com · 11d ago

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

globenewswire.com · 23d ago

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

globenewswire.com · 37d ago

Quince Therapeutics to Participate in September 2026 Investor Conferences

globenewswire.com · 57d ago

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Market news & ticker search · RSS for QNCX

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE